Citations to this article
Shen Dong, … , Qizhi Tang, Jeffrey A. Bluestone
Published July 29, 2021
Citation Information: JCI Insight. 2021;6(18):e147474. https://doi.org/10.1172/jci.insight.147474.
Citation Information: JCI Insight. 2021;6(18):e147474. https://doi.org/10.1172/jci.insight.147474.
Abstract
BACKGROUND A previous phase I study showed that the infusion of autologous Tregs expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent safety profile. However, the majority of the infused Tregs were undetectable in the peripheral blood 3 months postinfusion (Treg-T1D trial). Therefore, we conducted a phase I study (TILT trial) combining polyclonal Tregs and low-dose IL-2, shown to enhance Treg survival and expansion, and assessed the impact over time on Treg populations and other immune cells.METHODS Patients with T1D were treated with a single infusion of autologous polyclonal Tregs followed by one or two 5-day courses of recombinant human low-dose IL-2 (ld-IL-2). Flow cytometry, cytometry by time of flight, and 10x Genomics single-cell RNA-Seq were used to follow the distinct immune cell populations’ phenotypes over time.RESULTS Multiparametric analysis revealed that the combination therapy led to an increase in the number of infused and endogenous Tregs but also resulted in a substantial increase from baseline in a subset of activated NK, mucosal associated invariant T, and clonal CD8+ T cell populations.CONCLUSION These data support the hypothesis that ld-IL-2 expands exogenously administered Tregs but also can expand cytotoxic cells. These results have important implications for the use of a combination of ld-IL-2 and Tregs for the treatment of autoimmune diseases with preexisting active immunity.TRIAL REGISTRATION ClinicalTrials.gov NCT01210664 (Treg-T1D trial), NCT02772679 (TILT trial).FUNDING Sean N. Parker Autoimmune Research Laboratory Fund, National Center for Research Resources.
Authors
Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, Kevan C. Herold, Stephen E. Gitelman, Jonathan H. Esensten, Weihong Liu, Angela P. Lares, Ashley S. Leinbach, Michael Lee, Vinh Nguyen, Stanley J. Tamaki, Whitney Tamaki, Courtney M. Tamaki, Morvarid Mehdizadeh, Amy L. Putnam, Matthew H. Spitzer, Chun Jimmie Ye, Qizhi Tang, Jeffrey A. Bluestone
Citation information
Citations to this article (85)
| Title and authors | Publication | Year |
|---|---|---|
|
Metabolic reprogramming of naïve regulatory T cells by IL-7 and IL-15 promotes their persistence and performance upon adoptive transfer
Filoni J, Ferrari A, Jofra T, Putignano AR, Da Dalt L, Cesarano S, Di Dedda C, Bonacina F, Marchesi F, Norata D, Bonini C, Piemonti L, Monti P |
Communications Biology | 2025 |
|
Bronchus-associated lymphoid tissue in lung transplantation: a facilitator of rejection or regulator of tolerance?
Wein AN, Liu CR, Kreisel D |
Frontiers in Immunology | 2025 |
|
Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes.
Tuomela K, Levings MK |
Diabetologia | 2024 |
|
Tipping the balance towards transplantation tolerance: In vivo therapy using a mutated interleukin 2
Geoffrey Camirand, Fadi Lakkis |
Journal of Clinical Investigation | 2024 |
|
The immunology of type 1 diabetes.
Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK |
Nature reviews. Immunology | 2024 |
|
IL-27/Blimp-1 axis: a novel immune-tolerance regulator via inducing the Tim-3 expression in Treg cells during early pregnancy
SIJIA ZHAO, Xiao-Hui Hu, Xin-Xiu Lin, Yujing Zhang, Jing Wang, Huan Wang, Guang-Shun Gong, Gil Mor, Ai-Hua Liao |
JCI Insight | 2024 |
|
Assessing the effectiveness of Interleukin-2 therapy in experimental type 1 diabetes.
Luo Z, Mejia-Cordova M, Hamze N, Berggren E, Chopra S, Safi B, Blixt M, Sandler S, Singh K |
Endocrine | 2024 |
|
Aberrant NK cell profile in gestational diabetes mellitus with fetal growth restriction.
Xiong Y, Wang Y, Wu M, Chen S, Lei H, Mu H, Yu H, Hou Y, Tang K, Chen X, Dong J, Wang X, Chen L |
Frontiers in immunology | 2024 |
|
Enhancing Human Treg Cell Induction through Engineered Dendritic Cells and Zinc Supplementation
Shaikh NA, Zhang XB, Abdalla MI, Baylink DJ, Tang X |
Critical reviews in immunology | 2024 |
|
Emerging Strategies for Nanomedicine in Autoimmunity
Thatte AS, Billingsley MM, Weissman D, Melamed JR, Mitchell MJ |
Advanced Drug Delivery Reviews | 2024 |
|
The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis
Zhang SX, Chen HR, Wang J, Shao HF, Cheng T, Pei RM, Su QY, Zhang HY, Li XF |
Frontiers in immunology | 2024 |
|
The CD25-biased IL-2 SYNTHORIN™ molecule SAR444336 promotes the generation of functionally-adapted FoxP3+ regulatory T cells in a pre-clinical model of type 1 diabetes.
Fernando Alvarez, Nicole V. Acuff, Glen M. La Muraglia II, Nazila Sabri, Marcos E. Milla, Jill M. Mooney, Matthew F. Mackey, Mark Peakman, Ciriaco A. Piccirillo |
JCI Insight | 2024 |
|
Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection
Yang K, Zhang Y, Ding J, Li Z, Zhang H, Zou F |
Frontiers in Endocrinology | 2024 |
|
Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS, Stephenson AC, Leonard EK, VanDyke D, Spangler JB |
2024 | |
|
Immunotherapy in the context of sepsis-induced immunological dysregulation
Wu Y, Wang L, Li Y, Cao Y, Wang M, Deng Z, Kang H |
Frontiers in immunology | 2024 |
|
Low-dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation?
Amini L, Kaeda J, Weber O, Reinke P |
Transplantation | 2024 |
|
Peroxynitrite reduces Treg cell expansion and function by mediating IL-2R nitration and aggravates multiple sclerosis pathogenesis: One sentence summary: Peroxynitrite-mediated Treg IL-2R nitration impacts on multiple sclerosis
Wu M, Yu S, Yan S, Wu M, Zhang L, Chen S, Shi D, Liu S, Fan Y, Lin X, Shen J |
Redox Biology | 2024 |
|
Impacts of circulating cytokine levels and gene polymorphism predisposition on type 1 diabetes mellitus
Alghamdi AH, El-Sherbini SM, Shatla IM, Mady EA, El-Refaei MF |
Annals of Pediatric Endocrinology & Metabolism | 2024 |
|
Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations
Ge J, Yin X, Chen L |
Frontiers in Immunology | 2024 |
|
Quantifiable blood TCR repertoire components associate with immune aging
Hu J, Pan M, Reid B, Tworoger S, Li B |
Nature Communications | 2024 |
|
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Song Y, Li J, Wu Y |
Signal Transduction and Targeted Therapy | 2024 |
|
Interleukin-2 improves insulin sensitivity through hypothalamic sympathetic activation in obese mice.
Moon S, Park Y, Jang S, Kim S, Song DG, Shin DC, Lee CH |
Journal of neuroinflammation | 2024 |
|
T cell receptor–centric perspective to multimodal single-cell data analysis
Mullan KA, Ha M, Valkiers S, de Vrij N, Ogunjimi B, Laukens K, Meysman P |
Science Advances | 2024 |
|
From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases
Bulliard Y, Freeborn R, Uyeda MJ, Humes D, Bjordahl R, de Vries D, Roncarolo MG |
Frontiers in Immunology | 2024 |
|
Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
Ding JT, Yang KP, Lin KL, Cao YK, Zou F |
Frontiers in Endocrinology | 2023 |
|
Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes
Justin Spanier, Vivian Fung, Christine Wardell, Mohannad Alkhatib, Yixin Chen, Linnea Swanson, Alexander Dwyer, Matthew Weno, Nubia Silva, Jason Mitchell, Paul Orban, Majid Mojibian, C. Verchere, Brian Fife, Megan Levings |
Journal of Clinical Investigation | 2023 |
|
Clinical Manufacturing of Regulatory T Cell Products For Adoptive Cell Therapy and Strategies to Improve Therapeutic Efficacy
Baron KJ, Turnquist HR |
Organogenesis | 2023 |
|
T cells and their products in diabetic kidney disease
Liu Y, Lv Y, Zhang T, Huang T, Lang Y, Sheng Q, Liu Y, Kong Z, Gao Y, Lu S, Yang M, Luan Y, Wang X, Lv Z |
Frontiers in immunology | 2023 |
|
Role of Th17 cells, Treg cells, and Th17/Treg imbalance in immune homeostasis disorders in patients with chronic obstructive pulmonary disease
Ma R, Su H, Jiao K, Liu J |
Immunity, Inflammation and Disease | 2023 |
|
Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2
Tsyklauri O, Chadimova T, Niederlova V, Kovarova J, Michalik J, Malatova I, Janusova S, Ivashchenko O, Rossez H, Drobek A, Vecerova H, Galati V, Kovar M, Stepanek O |
eLife | 2023 |
|
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha R, Anderson KS |
Frontiers in Bioengineering and Biotechnology | 2023 |
|
Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes
Spanier JA, Fung V, Wardell CM, Alkhatib MH, Chen Y, Swanson LA, Dwyer AJ, Weno ME, Silva N, Mitchell JS, Orban PC, Mojibian M, Verchere CB, Fife BT, Levings MK |
2023 | |
|
Translating non-coding genetic associations into a better understanding of immune-mediated disease
Stankey CT, Lee JC |
Disease models & mechanisms | 2023 |
|
Opportunities for Treg cell therapy for the treatment of human disease
Bluestone JA, McKenzie BS, Beilke J, Ramsdell F |
Frontiers in immunology | 2023 |
|
The Role of Regulatory T Cells in the Onset and Progression of Primary Sjögren’s Syndrome
Blinova VG, Vasilyev VI, Rodionova EB, Zhdanov DD |
Cells | 2023 |
|
Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials
Arif S, Domingo-Vila C, Pollock E, Christakou E, Williams E, Tree TI |
Frontiers in immunology | 2023 |
|
Modeling cell-mediated immunity in human type 1 diabetes by engineering autoreactive CD8+ T cells
Peters LD, Yeh WI, Arnoletti JM, Brown ME, Posgai AL, Mathews CE, Brusko TM |
Frontiers in immunology | 2023 |
|
Overcoming Lung Cancer Immunotherapy Resistance by Combining Non-Toxic Variants Of IL-12 and IL-2
Brendan Horton, Alicia D'Souza, Maria Zagorulya, Chloe McCreery, Gita Abhiraman, Lora Picton, Allison Sheen, Yash Agarwal, Noor Momin, Karl Wittrup, Forrest White, K. Garcia, Stefani Spranger |
JCI Insight | 2023 |
|
Regulatory T cells in autoimmune kidney diseases and transplantation.
Mikami N, Sakaguchi S |
Nature reviews. Nephrology | 2023 |
|
Orchestrated regulation of immune inflammation with cell therapy in pediatric acute liver injury
Duan M, Liu X, Yang Y, Zhang Y, Wu R, Lv Y, Lei H |
Frontiers in immunology | 2023 |
|
GABA and Combined GABA with GAD65-Alum Treatment Alters Th1 Cytokine Responses of PBMCs from Children with Recent-Onset Type 1 Diabetes
Heath KE, Feduska JM, Taylor JP, Houp JA, Botta D, Lund FE, Mick GJ, McGwin G Jr, McCormick KL, Tse HM |
Biomedicines | 2023 |
|
Strategies to therapeutically modulate cytokine action.
Leonard WJ, Lin JX |
Nature reviews. Drug discovery | 2023 |
|
DRAK2 contributes to type 1 diabetes by negatively regulating IL-2 sensitivity to alter regulatory T cell development.
Mandarano AH, Harris TL, Creasy BM, Wehenkel M, Duggar M, Wilander BA, Mishra A, Crawford JC, Mullen SA, Williams KM, Pillai M, High AA, McGargill MA |
Cell Reports | 2023 |
|
"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".
Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM |
Genes and Immunity | 2023 |
|
Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy
Siddiqui K, Nawaz SS |
ImmunoTargets and Therapy | 2023 |
|
Editorial: New insights of immune cells in cardiovascular and metabolic disorders
Feng Y, Xiao X, Verfaillie C |
Frontiers in immunology | 2023 |
|
The role of inflammation in autoimmune disease: a therapeutic target
Xiang Y, Zhang M, Jiang D, Su Q, Shi J |
Frontiers in immunology | 2023 |
|
Precise surface functionalization of PLGA particles for human T cell modulation.
Hadley P, Chen Y, Cline L, Han Z, Tang Q, Huang X, Desai T |
Nature Protocols | 2023 |
|
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic LM, Liu K, VanDyke D, Fabilane CS, Spangler JB |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2023 |
|
Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge
Caldara R, Tomajer V, Monti P, Sordi V, Citro A, Chimienti R, Gremizzi C, Catarinella D, Tentori S, Paloschi V, Melzi R, Mercalli A, Nano R, Magistretti P, Partelli S, Piemonti L |
Frontiers in immunology | 2023 |
|
Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy
Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E, Papadopoulou A |
Cancers | 2023 |
|
Lower percentages of natural killer cells in children with type 1 diabetes and their siblings.
Sieniawska J, Krzewska A, Skowronek A, Wrobel W, Tomczyk Z, Pach E, Rosolowska I, Wilczynska B, Beń-Skowronek I |
Pediatric endocrinology, diabetes, and metabolism | 2023 |
|
Translation of Cell Therapies to Treat Autoimmune Disorders
Mehta JM, Hiremath SC, Chilimba C, Ghasemi A, Weaver JD |
Advanced Drug Delivery Reviews | 2023 |
|
Regulatory T Cells in Dominant Immunological Tolerance
Georgiev P, Benamar M, Han S, Haigis MC, Sharpe AH, Chatila TA |
Journal of Allergy and Clinical Immunology | 2023 |
|
Transplanted allogeneic stem cells secrete GDF-15 and stimulate an active immune remodeling process in the ischemic myocardium
Rachana Mishra, Progyaparamita Saha, Srinivas Raju datla, Pranav Mellacheruvu, muthukumar Gunasekaran, mir yasir arfat, xubin fu, ling chen, Roberto Bolli, Sudhish sharma, Sunjay Kaushal |
Journal of Translational Medicine | 2022 |
|
Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes
A Mitchell, A Michels |
International journal of molecular sciences | 2022 |
|
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?
C Deligne, S You, R Mallone |
Journal of Personalized Medicine | 2022 |
|
Regulatory T cells: A review of manufacturing and clinical utility
T Mamo, K Hippen, M MacMillan, C Brunstein, J Miller, J Wagner, B Blazar, D McKenna |
Transfusion | 2022 |
|
Engineering IL-2 for immunotherapy of autoimmunity and cancer
R Hernandez, J Põder, K LaPorte, T Malek |
Nature Reviews Immunology | 2022 |
|
Tissue Resident Foxp3+ Regulatory T Cells: Sentinels and Saboteurs in Health and Disease
J Lee, D Kim, B Min |
Frontiers in immunology | 2022 |
|
Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease
N Richardson, G Wootton, A Bozward, Y Oo |
Seminars in Immunopathology | 2022 |
|
Low Dose Interleukin-2 Ameliorates Sjögren’s Syndrome in a Murine Model
Wang Y, Feng R, Cheng G, Huang B, Tian J, Gan Y, Jin Y, Miao M, Zhang X, Sun X, He J, Li Z |
Frontiers in Medicine | 2022 |
|
Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease
Markovic M, Yeapuri P, Namminga KL, Lu Y, Saleh M, Olson KE, Gendelman HE, Mosley RL |
2022 | |
|
Nature vs. nurture: FOXP3, genetics, and tissue environment shape Treg function
Raugh A, Allard D, Bettini M |
Frontiers in immunology | 2022 |
|
Immunopathogenesis and environmental triggers in coeliac disease
Levescot A, Malamut G, Cerf-Bensussan N |
Gut | 2022 |
|
Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjögren’s syndrome
Wen J, Zhu F, Yu X, Xie H, Li C |
BMC Immunology | 2022 |
|
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SC, Kim S, Burden A, Alho AC, Lacerda JF, Alyea EP, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J, Koreth J |
Blood Advances | 2022 |
|
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry JA, Gebara E, Cross AR, Cheung LS, Dykema AG, Orcutt-Jahns BT, Henclová T, Golias J, Balolong J, Tomasovic LM, Funda D, Meyer AS, Pardoll DM, Hester J, Issa F, Hunter CA, Anderson MS, Bluestone JA, Raimondi G, Spangler JB |
Cell Reports | 2022 |
|
Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development
Du C, Whiddett RO, Buckle I, Chen C, Forbes JM, Fotheringham AK |
Cells | 2022 |
|
Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation
Sanders JM, Jeyamogan S, Mathew JM, Leventhal JR |
Frontiers in immunology | 2022 |
|
Biomaterials-Based Nanoparticles Conjugated to Regulatory T Cells Provide a Modular System for Localized Delivery of Pharmacotherapeutic Agents
Marshall G, Cserny J, Wang CW, Looney B, Posgai AL, Bacher R, Keselowsky B, Brusko TM |
Journal of biomedical materials research. Part A | 2022 |
|
Clinical and experimental treatment of type 1 diabetes: Perspectives on immunopathology and Clinical and experimental treatment of type 1 diabetes
Long SA, Buckner JH |
Clinical & Experimental Immunology | 2022 |
|
The emerging role of regulatory cell-based therapy in autoimmune disease
Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M, Rezaei-Tazangi F, Khorram R, Afshinpour M, Robino RA, Aref AR, Ferreira LM |
Frontiers in immunology | 2022 |
|
Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors.
Kremer J, Henschel P, Simon D, Riet T, Falk C, Hardtke-Wolenski M, Wedemeyer H, Noyan F, Jaeckel E |
Frontiers in immunology | 2022 |
|
Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers
Verreycken J, Baeten P, Broux B |
Human Vaccines & Immunotherapeutics | 2022 |
|
Contribution of adaptive immunity to human COPD and experimental models of emphysema
Kheradmand F, Zhang Y, Corry DB |
Physiological reviews | 2022 |
|
The potential for treg-enhancing therapies in nervous system pathologies
Olson KE, Mosley RL, Gendelman HE |
Clinical & Experimental Immunology | 2022 |
|
IL-2-based approaches to Treg enhancement
Harris F, Berdugo YA, Tree T |
Clinical & Experimental Immunology | 2022 |
|
Regulatory T-cell therapy approaches
McCallion O, Bilici M, Hester J, Issa F |
Clinical & Experimental Immunology | 2022 |
|
Antigen-specific immunotherapy to restore antigen-specific tolerance in Type 1 diabetes and Graves’ disease
Zala A, Thomas R |
Clinical & Experimental Immunology | 2022 |
|
The potential for Treg-enhancing therapies in tissue, in particular skeletal muscle, regeneration
Hanna BS, Yaghi OK, Langston PK, Mathis D |
Clinical & Experimental Immunology | 2022 |
|
Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans.
Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, Lee K, Greenland JR, Hellerstein M, Fitch M, Li KW, Esensten JH, Putnam AL, Lares A, Nguyen V, Liu W, Bridges ND, Odim J, Demetris AJ, Levitsky J, Taner T, Feng S |
Science Translational Medicine | 2022 |
|
Regulatory T Cell Therapeutics for Neuroinflammatory Disorders.
Harkins AL, Kopec AL, Keeler AM |
Critical reviews in immunology | 2022 |
|
100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes
J Pearson, E McKinney, L Walker |
2021 | |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
